Wilms’ Tumor 1 (WT1): The Vaccine for Cancer

Abstract

Vaccines have been used to fight and protect against infectious diseases for centuries. With the emergence of immunotherapy in cancer treatment, researchers began investigating vaccines that could be used against cancer, especially against tumors that are resistant to conservative chemotherapy, surgery, and radiotherapy. The Wilms’ tumor 1 (WT1) protein is immunogenic, has been detected in almost all types of malignancies, and has played a significant role in prognosis and disease monitoring. In this article, we review recent developments in the treatment of various types of cancers with the WT1 cancer vaccine; we also discuss theoretic considerations of various therapeutic approaches, which were based on preclinical and clinical data.

Keywords

• peptide-based vaccine
• immunotherapy
• wt1 gene
• leukemia
• solid cancer
• toxicity
• preclinical trails
• clinical trials
• cancer medicine
• cancer vaccine